Molecular and Genetic Analysis of Lung Cancer
- Conditions
- Lung Cancer
- Registration Number
- NCT03029325
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
- Detailed Description
Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 15000
- healthy controls: participants without evidence of any cancer
- cases: pathology proven primary lung cancer
- younger than 18 years old
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression 20 years Study lung cancer development in a case control study. We will look at three separate outcome measures specified below
- Secondary Outcome Measures
Name Time Method Overall survival 20 years Measurement from time of diagnosis to death will be obtained
Progression-free survival 20 years Time of diagnosis to disease progression (measured by metastasis)
Treatment toxicities 20 years Effects on ECOG and physical sequelae from treatment (radiation, chemotherapy and other treatment modalities will be analyzed)
Trial Locations
- Locations (1)
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States